My ePortfolio Register   

FDA approves obinutuzumab for previously untreated follicular lymphoma

The US Food and Drug Administration has granted regular approval to obinutuzumab in combination with chemotherapy, followed by obinutuzumab monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL).

Approval was based on a multicenter, open-label, randomized phase 3 trial (GALLIUM) for patients with previously untreated non-Hodgkin lymphoma, including 1202 patients with FL.

Patients were randomized 1:1 to receive either obinutuzumab chemotherapy or rituximab chemotherapy, followed in responding patients by obinutuzumab or rituximab maintenance for up to 2 years.

Of the patients with FL, 91% had stage III-IV disease, 44% had bulky disease, and 79% had at least intermediate-risk disease.

The chemotherapy backbone was bendamustine in 57%, CHOP in 33% and CVP in 10%.

With a median follow-up of 38 months, progression-free survival, as assessed by an independent review committee, was statistically significantly improved in the obinutuzumab arm, with an estimated hazard ratio of 0.72 (95% CI: 0.56, 0.93; p=0.0118) compared to the rituximab arm.

Median progression-free survival was not reached in either arm.

As assessed by CT, the arms had similar overall response rates (91% with obinutuzumab, 88% with rituximab) and complete remission rates (28% and 27%, respectively).

Among the 1385 patients evaluated for safety, the obinutuzumab arm had higher incidences of serious adverse reactions (ARs; 50% compared to 43% in the rituximab arm), grade ≥ 3 ARs (79% vs. 72%) and fatal infections (2% vs. < 1%).

The most common ARs in the obinutuzumab arm (incidence ≥ 20% and ≥ 2% greater than in the rituximab arm) included infusion reactions, neutropenia, upper respiratory tract infection, cough, constipation and diarrhoea.

The most common grade ≥ 3 ARs (incidence ≥ 5%) observed more frequently with obinutuzumab were neutropenia, febrile neutropenia, thrombocytopenia and infusion reactions.

Recipients of bendamustine had higher incidences of serious and fatal infections than recipients of CHOP or CVP.

In patients with previously untreated FL, the recommended dose-schedule of obinutuzumab is 1000 mg intravenously on days 1, 8 and 15 of cycle 1; 1000 mg on day 1 of cycles 2-6 or cycles 2-8; and then 1000 mg every 2 months for up to 2 years.

Source: FDA



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence